Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study

被引：0

作者：

Ferrante, M. ^{[1
]}

Feagan, B. G. ^{[2
]}

Panes, J. ^{[3
]}

Baert, F. ^{[4
]}

Louis, E. ^{[5
,6
]}

Dewit, O. ^{[7
]}

Kaser, A. ^{[8
]}

Duan, W. R. ^{[9
]}

Gustafson, D. ^{[10
]}

Liao, X. ^{[11
]}

Wallace, K. ^{[10
]}

Kalabic, J. ^{[12
]}

D'Haens, G. R. ^{[13
]}

机构：

[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium

[2] Univ Western Ontario, Clin Trials Design & Management, London, ON, Canada

[3] Hosp Clin Barcelona, Dept Inflammatory Dis, Barcelona, Spain

[4] AZ Delta, Dept Gastroenterol, Roeselare Menen, Belgium

[5] Univ Liege, Dept Gastroenterol, Liege, Belgium

[6] CHU Liege, Liege, Belgium

[7] Clin Univ St Luc, Dept Gastroenterol, Brussels, Belgium

[8] Univ Cambridge, Dept Gastroenterol, Cambridge, England

[9] AbbVie Inc, Dept Pharmacovigilance & Patient Safety, N Chicago, IL USA

[10] AbbVie Inc, Dept Immunol, N Chicago, IL USA

[11] AbbVie Inc, Dept Data & Stat Sci, N Chicago, IL USA

[12] AbbVie Deutschland GmbH & Co KG, Dept Immunol, Ludwigshafen, Germany

[13] Univ Amsterdam, Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷

关键词：

MODERATE;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OP27

引用

页码：S024 / S025

页数：2

共 4 条

[1] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Feagan, Brian G.
Panes, Julian
Ferrante, Marc
Kaser, Arthur
D'Haens, Geert R.
Sandborn, William J.
Louis, Edouard
Neurath, Markus F.
Franchimont, Denis
Dewit, Olivier
Seidler, Ursula
Kim, Kyung-Jo
Selinger, Christian
Padula, Steven J.
Herichova, Ivona
Robinson, Anne M.
Wallace, Kori
Zhao, Jun
Minocha, Mukul
Othman, Ahmed A.
Soaita, Adina
Visvanathan, Sudha
Hall, David B.
Boecher, Wulf O.
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10) : 671 - 680
[2] Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Feagan, Brian G.
Sandborn, William J.
D'Haens, Geert
Panes, Julian
Kaser, Arthur
Ferrante, Marc
Louis, Edouard
Franchimont, Denis
Dewit, Olivier
Seidler, Ursula
Kim, Kyung-Jo
Neurath, Markus F.
Schreiber, Stefan
Scholl, Paul
Pamulapati, Chandrasena
Lalovic, Bojan
Visvanathan, Sudha
Padula, Steven J.
Herichova, Ivona
Soaita, Adina
Hall, David B.
Bocher, Wulf O.
[J]. LANCET, 2017, 389 (10080) : 1699 - 1709
[3] Ferrante M, 2018, UEG J, V6
[4] DEFINING PATIENT-CENTERED OUTCOMES FOR IBD AND AN INTERNATIONAL, CROSS-DISCIPLINARY CONSENSUS
Kim, Andrew H.
Roberts, Charlotte
Feagan, Brian G.
Banerjee, Rupa
Bemelman, Willem
Bodger, Keith
Derieppe, Marc
Dignass, Axel
Driscoll, Richard
Fitzpatrick, Ray
Higgins, Peter D.
Kotze, Paulo G.
Meissner, Jillian
O'Connor, Marian
Ran, Zhihua
Siegel, Corey A.
Terry, Helen
van Deen, Welmoed K.
Van der Woude, Christien Janneke
Weaver, Alandra
Yang, Suk-Kyun
Sands, Bruce E.
Vermeire, Severine
Travis, Simon P.
[J]. GASTROENTEROLOGY, 2017, 152 (05) : S137 - S138

← 1 →